Mechanisms of aluminium neurotoxicity in oxidative stress-induced ...

REFERENCES
Miu A. C. and Benga O. (2006) Aluminum and Alzheimer's disease: a new look. J. Alzheimers
220
Dis. 10, 179–201.
Mogi M., Harada M., Riederer P., Narabyashi H., Fujita J. and Nagatsu T. (1994) Interleukin-1
beta growth factor and transforming growth factor-alpha are elevated in the brain from
Parkinsonian patients. Neurosci. Lett. 180, 147–150.
Moore D. J., West A. B., Dawson V. L. and Dawson T. M. (2005) Molecular pathophysiology of
Parkinson's disease. Annu. Rev. Neurosci. 28, 57–87.
Moore P. B., Day J. P., Taylor G. A., Ferrier I. N., Fifield L. K. and Edwardson J. A. (2000)
Absorption of 26aluminium in Alzheimer’s disease, measured using accelerator mass
spectrometry. Dement. Geriatr. Cogn. Disord. 11, 66–69.
Morens D. M., Grandinetti A., Reed D., White L. R. and Ross G. W. (1995) Cigarette smoking
and protection from Parkinson’s disease: false association or etiologic clue? Neurology 45,
1041–1051.
Morgante L., Rocca W. A., Di Rosa A. E., De Domenico P., Grigoletto F., Meneghini F., Reggio A.,
Savettieri G., Castiglione M. G., Patti F. and Di Pierri R. (1992) Prevalence of Parkinson’s
disease and other types of parkinsonism: a door-to-door survey in three Sicilian
municipalities. Neurology 42, 1901–1907.
Morrish P. K., Sawle G. V., Brooks D. J. (1996) An [18F]dopa-PET and clinical study of the rate of
progression in Parkinson’s disease. Brain 119, 585–591.
Mosharov E. V., Staal R. G., Bove J., Prou D., Hananiya A., Markov D., Poulsen N., Larsen K. E.,
Moore C. M., Troyer M. D., Edwards R. H., Przedborski S. and Sulzer D. (2006)
Alphasynuclein overexpression increases cytosolic catecholamine concentration. J.
Neurosci. 26, 9304–9311.
Moumen R., Ait-Oukhatar N., Bureau F., Fleury C., Boublé D., Arhan P., Neuville D. and Viader
F. (2001) Aluminium increases xanthine oxidase activity and disturbs antioxidant status in
the rat. J. Trace Elem. Med. Biol. 15, 89–93.